ATC Group: R06AA04 Clemastine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R06AA04 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R06 Antihistamines for systemic use
3 R06A Antihistamines for systemic use
4 R06AA Aminoalkyl ethers
5 R06AA04 Clemastine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 2 mg
PAREN - Parenteral 2 mg

Active ingredients in R06AA04

Active Ingredient Description
Clemastine

Clemastine is an H1-receptor antagonist. It inhibits selectively the histamine receptors of the H1 type and reduces capillary permeability. It exerts a potent antihistaminic and antipruritic effect with a fast onset and long duration of action.

Related product monographs

Title Information Source Document Type  
TAVEGIL Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Ecuador (EC)

Estonia (EE)

Germany (DE)

Hong Kong (HK)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

South Africa (ZA)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.